212 related articles for article (PubMed ID: 1292974)
1. Bone turnover in overt and subclinical hyperthyroidism due to autonomous thyroid adenoma.
De Menis E; Da Rin G; Roiter I; Legovini P; Foscolo G; Conte N
Horm Res; 1992; 37(6):217-20. PubMed ID: 1292974
[TBL] [Abstract][Full Text] [Related]
2. [Serum osteocalcin in hyperthyroidism].
Roiter I; Legovini P; Da Rin G; Galliazzo S; Di Virgilio R; Foscolo G; Breda F; Conte N
Ann Ital Med Int; 1990; 5(2):95-9. PubMed ID: 2248865
[TBL] [Abstract][Full Text] [Related]
3. Bone remodelling markers and serum cytokines in patients with hyperthyroidism.
Akalin A; Colak O; Alatas O; Efe B
Clin Endocrinol (Oxf); 2002 Jul; 57(1):125-9. PubMed ID: 12100080
[TBL] [Abstract][Full Text] [Related]
4. Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women.
Gürlek A; Gedik O
Thyroid; 1999 Jun; 9(6):539-43. PubMed ID: 10411115
[TBL] [Abstract][Full Text] [Related]
5. Sclerostin and bone metabolism markers in hyperthyroidism before treatment and interrelations between them.
Sarıtekin İ; Açıkgöz Ş; Bayraktaroğlu T; Kuzu F; Can M; Güven B; Mungan G; Büyükuysal Ç; Sarıkaya S
Acta Biochim Pol; 2017; 64(4):597-602. PubMed ID: 29059259
[TBL] [Abstract][Full Text] [Related]
6. Biochemical markers of bone turnover in patients with thyroid dysfunctions and in euthyroid controls: a cross-sectional study.
Engler H; Oettli RE; Riesen WF
Clin Chim Acta; 1999 Nov; 289(1-2):159-72. PubMed ID: 10556662
[TBL] [Abstract][Full Text] [Related]
7. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism.
Kumeda Y; Inaba M; Tahara H; Kurioka Y; Ishikawa T; Morii H; Nishizawa Y
J Clin Endocrinol Metab; 2000 Nov; 85(11):4157-61. PubMed ID: 11095447
[TBL] [Abstract][Full Text] [Related]
8. Effect of thyroxine therapy on bone metabolism in substituted hypothyroid patients with normal or suppressed levels of TSH.
Gam AN; Jensen GF; Hasselstrøm K; Olsen M; Nielsen KS
J Endocrinol Invest; 1991 Jun; 14(6):451-5. PubMed ID: 1774441
[TBL] [Abstract][Full Text] [Related]
9. Serum osteocalcin levels in hyperthyroidism before and after antithyroid therapy.
Barsal G; Taneli F; Atay A; Hekimsoy Z; Erciyas F
Tohoku J Exp Med; 2004 Jul; 203(3):183-8. PubMed ID: 15240927
[TBL] [Abstract][Full Text] [Related]
10. Estimation of bone turnover evaluated by 47Ca-kinetics. Efficiency of serum bone gamma-carboxyglutamic acid-containing protein, serum alkaline phosphatase, and urinary hydroxyproline excretion.
Charles P; Poser JW; Mosekilde L; Jensen FT
J Clin Invest; 1985 Dec; 76(6):2254-8. PubMed ID: 3878367
[TBL] [Abstract][Full Text] [Related]
11. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism.
Mudde AH; Houben AJ; Nieuwenhuijzen Kruseman AC
Clin Endocrinol (Oxf); 1994 Oct; 41(4):421-4. PubMed ID: 7955452
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Biondi B; Iorio S; Giustina A; Amato G; Carella C
J Bone Miner Res; 2005 Mar; 20(3):480-6. PubMed ID: 15746993
[TBL] [Abstract][Full Text] [Related]
13. Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism.
Kisakol G; Kaya A; Gonen S; Tunc R
Endocr J; 2003 Dec; 50(6):657-61. PubMed ID: 14709834
[TBL] [Abstract][Full Text] [Related]
14. Bone mass, bone turnover, calcium homeostasis, and body composition in surgically and radioiodine-treated former hyperthyroid patients.
Langdahl BL; Loft AG; Eriksen EF; Mosekilde L; Charles P
Thyroid; 1996 Jun; 6(3):169-75. PubMed ID: 8837322
[TBL] [Abstract][Full Text] [Related]
15. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?
Langdahl BL; Loft AG; Møller N; Weeke J; Eriksen EF; Mosekilde L; Charles P
J Bone Miner Res; 1997 Jan; 12(1):78-88. PubMed ID: 9240729
[TBL] [Abstract][Full Text] [Related]
16. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
[TBL] [Abstract][Full Text] [Related]
17. Approach to the patient with subclinical hyperthyroidism.
Cooper DS
J Clin Endocrinol Metab; 2007 Jan; 92(1):3-9. PubMed ID: 17209221
[TBL] [Abstract][Full Text] [Related]
18. [Serum levels of the tartrate-resistant isoenzyme, acid phosphatase, for the evaluation of bone remodeling in hyperthyroidism].
Legovini P; De Menis E; Da Rin G; Roiter I; Breda F; Conte N
Minerva Endocrinol; 1994 Sep; 19(3):133-8. PubMed ID: 7799895
[TBL] [Abstract][Full Text] [Related]
19. Serum bone Gla protein: a marker of bone turnover in hyperthyroidism.
Garrel DR; Delmas PD; Malaval L; Tourniaire J
J Clin Endocrinol Metab; 1986 May; 62(5):1052-5. PubMed ID: 3485649
[TBL] [Abstract][Full Text] [Related]
20. Markers of bone turnover in hyperthyroidism and the effects of treatment.
Garnero P; Vassy V; Bertholin A; Riou JP; Delmas PD
J Clin Endocrinol Metab; 1994 Apr; 78(4):955-9. PubMed ID: 8157727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
